Discovery may pave way for preventing diabetes-associated blindness

Discovery may pave way for preventing diabetes-associated blindness


Diabetic retinopathy is one of the most common cause of vision loss in adults suffering from diabetes and currently available medicines, though slow the progression of the diseases, do not offer complete prevention. Looking for an answer that could prevent the occurrence of diabetes-associated blindness, researchers at The Johns Hopkins University and the University of Maryland set out to look for a more effective treatment.

Diabetic retinopathy occurs when the normal blood vessels in the eye are replaced over time with abnormal, leaky, fragile blood vessels that leak fluid or bleed into the eye, damaging the light-sensitive retina and causing blindness.

One of the most used procedures to treat this disorder is laser-sealing eye blood vessels. This method effectively saves the central vision, but is many cases patients have to sacrifice their peripheral and night vision says Akrit Sodhi, M.D., Ph.D. , an assistant professor of ophthalmology at the Johns Hopkins University School of Medicine.

Pharma companies have come up with several drugs recently — bevacizumab, ranibizumab and aflibercept — that are pegged as effective treatment for diabetes-associated blindness. These drugs act on the blood vessels that cause the blindness by blocking the action of VEGF, a so-called growth factor released as part of a chain of signals in response to low oxygen levels, which stimulates the growth of new, often abnormal, blood vessels. But, subsequent studies have pegged these drugs as rather a hurdle that slows progression to proliferative diabetic retinopathy, and that they do not reliably prevent it.

Researchers of the new study published online May 25 in Proceedings of the National Academy of Sciences, started looking for an explanation as to why does blocking of VEGF doesn’t completely prevent the disease.

Postdoctoral fellow Savalan Babapoor-Farrokhran, M.D., and Kathleen Jee, a student at the school of medicine who will begin her residency in ophthalmology at the Wilmer Eye Institute at Johns Hopkins next year, tested levels of VEGF in samples of fluid from the eye taken from healthy people, people with diabetes who did not have diabetic retinopathy and people with diabetic retinopathy of varying severity.

According to the findings, while levels of VEGF tended to be higher in those with proliferative diabetic retinopathy, some of their fluid had less VEGF than did the healthy participants. But even the low-VEGF fluid from patients with proliferative diabetic retinopathy stimulated blood vessel growth in lab-grown cells.

“The results suggested to us that although VEFG clearly plays an important role in blood vessel growth, it’s not the only factor,” Sodhi says.

Carrying out a series of experiments in lab-grown human cells and mice revealed a second culprit, a protein called angiopoietin-like 4. Blocking the actions of both VEGF and angiopoietin-like 4 in fluid from the eyes of people with proliferative diabetic retinopathy, resulted in reduced blood vessel growth in lab-grown cells.

This researchers say could be the answer they were looking for. According to researchers if a drug can be found that safely blocks the second protein’s action in patients’ eyes, it might be combined with the anti-VEGF drugs to prevent many cases of proliferative diabetic retinopathy, Sodhi suggests.

The team is now investigating whether angiopoietin-like 4 might also play a role in other eye diseases, such as macular degeneration, which destroys the central portion of the retina.


Medela dumped Molnlycke in return molnlycke partnered with Talley

Talley Group Ltd Announces Supply Agreement with Mölnlycke Health Care

Talley Group Ltd, the privately owned British Manufacturer of medical devices is pleased to announce its collaboration with Mölnlycke Health Care for the supply of Negative Pressure Wound Therapy devices under their Avance® brand in the US market.

Talley Group Ltd has been supplying NPWT systems to the international market for almost a decade.  From its headquarters in Hampshire, UK, all research, product development and manufacturing is carried out under one roof and product shipped around the globe.

This agreement with a world-leading provider of single-use surgical and wound care products brings together two companies to collectively deliver a high quality, robust and reliable mechanical device, combined with the advanced and clinically proven dressing technology Safetac®, the gentle adhesive film that ensures minimised pain and offers time saving benefits.

Chris Evans, CEO of Talley Group comments:

As a vertically integrated UK manufacturing organisation, we strive to offer the very best quality products to our global customer base. This collaboration clearly demonstrates that experts in wound care also recognise this level of workmanship and we are excited to be collaborating with such a well-respected and innovative wound care organisation.

Steve Atlay, Global Business Director NPWT for Mölnlycke Health Care comments:

We have a clear ambition to continue to develop and enhance our Negative Pressure Wound Therapy offering. Our partnership with Talley Group Ltd will enable us to support these aims in the US market while delivering a first-class solution to our customers and patients.

Equinox Medical, LLC is one of the leading negative pressure wound therapy pump system manufacturer and NPWT black foam dressing. The company launched their halo mini negative pressure wound therapy pump system in the US and Europe last year.

New Clinical Data on the Role of Nexodyn™ in the Management of Infected Chronic Wounds of the Lower Leg Presented at

New Clinical Data on the Role of Nexodyn™ in the Management of Infected Chronic Wounds of the Lower Leg Presented at EWMA (European Wound Management Association, London, 13-15 May 2015)

BALERNA, Switzerland–(BUSINESS WIRE)–APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science-driven, patent-protected healthcare products, communicates that new clinical data on the role of Nexodyn™, an AcidOxidizing spray solution, in the management of infected chronic wounds have been presented by Elia Ricci, MD, and colleagues at the EWMA (European Wound Management Association) 2015 Conference in London (May 13 – 15).

These data clearly demonstrates that the use of Nexodyn alone is able to control the local bioburden in wounds showing clinical signs of infection and provides local microenvironmental modulation helping wounds reset and restart a physiological healing process, a hot topic in the bio-medical field.

The presented data report the results of a retrospective analysis on 9 patients with infected chronic ulcers of different etiology which were showing unsatisfactory progress with standard therapies. With the objective of providing patients with a cleansing treatment able to satisfactorily control the local signs of infection, patients included in analysis received Nexodyn™ once daily for 4 weeks with no other active treatment.
After 4 weeks of treatment with Nexodyn only, used to cleanse the wound bed at each medication, infection rates showed a statistically significant reduction of local infection, with 75% of patients devoid of any signs of local infection. In parallel, indicators of the wound bed quality and its microenvironment, such as the WBP Total Score, the multi-factorial Bates-Jensen Score showed significantly improved wound conditions. The progressive evaluation of an easy-to-measure indicator of the local microenvironmental conditions, the local pH, whose decrease is an indicator of wound healing, showed a trend of reduction despite the relatively short observation time. In addition, wound-associated pain decreased significantly, providing a definitive benefit to patients.
In the context of EWMA 2015, APR is proud to announce to be one of the sponsors of the Antimicrobial Stewardship in Wound gathering worldwide renown experts discussing on the topic: “Combatting Antimicrobial Misuse in Wound Care”.
A recognized general misuse of systemic and local antibiotics, together with the alarming raise of multi-resistant bacterial strains, pose important challenges to wound management, where one of the most frequent complications is certainly infection.
The Antimicrobial Stewardship in Wound Management has the objective to strengthen the knowledge of all the healthcare stakeholders by setting the basis for the identification of best practices in prevention, diagnosis and treatment of wound infection and to foster education in the chronic wound setting.

About Nexodyn™
Nexodyn is an AcidOxidizing spray solution, characterized by pH<3, RedOx >1000mV and stabilized hypochlorous acid (>95% of free chlorine species) – intended for use in the debridement, irrigation and moistening of acute and chronic wounds, ulcers, cuts, abrasions, burns and other lesions.
Nexodyn has been developed based on APR’s proprietary and patented technology TEHCLO®, enabling the production of super-oxidized solutions containing free chlorine species, of which stabilized hypochlorous acid (HClO) in very high concentration (> 95%). A wide array of non-clinical experiments and clinical observations suggest Nexodyn to act as a valid support to the activation of the physiological processes that restart wound healing, in presence of a favorable safety and tolerability profile.
The convenient and easy-to-use spray formulation completes Nexodyn’s profile, providing healthcare professionals with a new tool for an optimized wound care.

About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutical areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a

The best negative pressure wound therapy pump system is now available in the United States. Equinox Medical introduced the halo mini negative pressure wound therapy pump system is a portable and powerful pump system.

Equinox Medical is not offering capital finance for your NPWT pump system purchase

EquinoxO2 Medical, LLC

Equinox Medical is happy to offer you free financing for thirty days thru Direct Capital.OFFER EXPIRES JUNE 30,2015

Terms and Conditions







We are here to help you expand your capital by offering affordable credit rates whether is dressings or NPWT devices, please take advantage of this opportunity. Please click here Finanace Application to fill out our application. Remember you have until June 30,2015 to apply.

describe the image

New Jersey’s Dr. Parker Explains Scar Prevention Techniques and Incision Care for Ethnic Patients

PARAMUS, N.J., May 5, 2015 /PRNewswire/ — According to a study by the Henry Ford Hospital, African Americans are seven times more likely than Caucasians to develop keloid scarring following head and neck surgery. As a board certified plastic surgeon, Dr. Paul M. Parker understands this better than most and works closely with patients to reduce the risk of developing excessive scarring after plastic surgery.

There are two main types of scars that ethnic patients are prone to encounter: keloid and hypertrophic scars. Keloids are shiny, raised scars that sit above the surrounding skin. Hypertrophic scars are raised, firm scars that typically become less visible within six months of surgery for Caucasian patients, but may not fade for those of Asian, Hispanic, or African descent. Common surgical areas, such as the neck, head, and ears, are at greater risk for scarring in these patients.

“Many of my patients of African, Caribbean, or south Indian descent are particularly, and understandably, concerned about scarring,” says Dr. Parker. “I use several techniques to help prevent keloid scarring in my patients with darker skin.”

In addition to educating patients on how to avoid scarring, Dr. Parker utilizes special methods for lowering the risk of keloid scar development. During surgery, Dr. Parker carefully prepares the skin so that it can glide more easily into place and heal naturally. He also places dissolvable stitches in both the subcutaneous tissue and deep dermis to prevent putting unnecessary pressure on the wound. This tension-free closure stays in place for several weeks or months as the patient heals and helps promote proper incision healing.

“I have helped many keloid-prone patients avoid scarring through careful pre-operative and postsurgical approaches,” Dr. Parker explains. “Here at the Parker Center for Plastic Surgery, we work to avoid unnecessary scarring in all patients.”

Dr. Parker stresses the necessity of proper wound and incision care following surgery, and developed a Rapid Recovery Program that helps patients minimize downtime and maximize proper wound healing. For patients with darker skin, this is particularly important, and Dr. Parker works with these patients to develop the best postoperative scar care plan for each individual. He often recommends a specialized scar cream and/or silicone adhesives to improve the quality of the scar. Each patient receives information about the proper way to apply the scar cream and is encouraged to continue a regular skincare routine to promote overall skin health.

“Scarring in darker skin can be reduced by paying careful attention to the wound during and following surgery,” notes Dr. Parker. “Patients from all backgrounds deserve smooth, subtle scars in the months and years after surgery.”

Portable Halo MINI NPWT Vac System will help heal any pressure ulcers or bedsores

halo mini negative pressure wound therapy pump system

US Patients are missing out on HeartWare

Could HeartWare’s U.S. Patients Be Missing Out?

HeartWare is planning to take a closer look at a pulsatility algorithm built into its LVADs outside the United States to find out if it potentially offers clinical benefits.

The Lavare algorithm is included in HeartWare’s international HVADs, but not in domestic devices.

HeartWare, one of two major makers of left ventricular assist devices (LVADs) in the United States, will begin to investigate the potential effects of a pulsatility algorithm that it has long included in its international devices but not in its domestic LVADs. The company’s decision to make a closer examination of the technology, called the Lavare algorithm, stems from research presented recently at the International Society for Heart and Lung Transplantation (ISHLT) annual meeting in Nice, France.

LVADs move blood from the left ventricle of the heart into the aorta, where it is the delivered to the rest of the body. Normally, in healthy patients, blood is pumped from the left ventricle through the aortic valve into the aorta. As explained in earlier research, LVAD therapy is thought to change the aortic valve by altering pressure, either leaving too little blood volume in the left ventricle—leading the aortic valve, if opened, to have a smaller opening for a shorter period of time—or by giving the aortic valve no reason to open at all, since the pump delivers the blood from the left ventricle to the aorta.

On the April 30 HeartWare earnings call, chief executive officer Doug Godshall explained that pumps with the Lavare algorithm “slow down briefly . . . allows the ventricule to fill, and the ventricle should then have enough volume to eject normally through the aortic valve . . .”

Godshall was referring to research presented by Diyar Saeed MD, PhD, from Heinrich-Heine University in Dusseldorf, Germany at the ISHLT meeting in mid-April. The research, which Saeed conducted with colleagues, is titled “Intermittent Low Speed Software (ILS) May Reduce the Prevalence of De Novo Aortic Insufficiency in Patients Supported With HeartWare HVAD Pump.” Saeed noted that new aortic valve insufficiency (AI) is found in 11-42% of patients implanted with the competitive Thoratec HeartMate II LVAD and that a closed aortic valve is known to be a contributing factor.

Saeed points out that HeartWare’s European HVAD has “intermittent low speed (ILS) software,” the Lavare algorithm, which allows the aortic valve to open sometimes. To test whether ILS software (the algorithm) would cut the observed rate of AI, he implanted 34 patients with the HVAD and turned on ILS two weeks after the procedure. Of the 31 patients eligible for analysis—the other three patients were excluded from analysis because of prior aortic valve surgery—the median time on LVAD therapy was 350 days (ranging from 66–1250 days). Trace AI was observed in four patients (13%) and mild AI in two patients (6%). Opening of the aortic valve (in at least 3 of 10 beats) was seen in all the patients but one, who developed moderate AI following six months of LVAD therapy. After being put on antihypertensive therapy this patient improved to mild AI.

Though a small study, Saeed felt that the lower rate of AI seen in these patients could be explained by more frequent aortic valve opening and the ILS software.

Although the Lavare algorithm software is used in HVADs outside the United States, it was not included in the company’s US approval trial. Godshall explained to analysts on the earnings call, “we had already used it [the Lavare algorithm] in our international trial but the FDA at that time . . . had questions that we just were unable to answer in 2007 and 2008. And so rather than hold up the start of our trial . . . we realized it was going to materially delay our ability to start our trial just to try to answer their question.”

The Lavare algorithm is used in many international centers on all HVAD patients and was used in approximately 80% of patients in the recent REVOLVE trial, Godshall said. “Until recently . . . it was a nice feature that our physicians liked, but there was not a lot of evidence to point to that said hey, this is something we really need to pull into the U.S. . . The Europeans would certainly be very upset if we took it away.”

Now, Godshall said, the company has discussed the algorithm with the agency and FDA seems to be open to allowing its use in U.S. HVADs. “We expect to file amendment on this in the very near-term,” he said. He noted that in the discussion with FDA, HeartWare has not been trying to claim any benefit from the algorithm, but just explaining its function. The company is working with the agency to find “the least burdensome path to get it approved,” he said.

Equinox Medical, LLC currently sells their FDA approved Halo MINI NPWT Pump, Halo XT NPWT Pump, Cobaltt NPWT Pump and Black Foam Wound Dressing Kits in the US, Europe and Turkey.

Halo MINI NPWT Rental Pump

Halo MINI NPWT Rental Pump

FDA Application for CyPass Micro Stent

VIDEO: Transcend Medical preparing FDA application for CyPass micro-stent

Transcend Medical plans to file a premarket approval application with the FDA later this year for the CyPass micro-stent, the company announced in a press release.

The COMPASS trial, a prospective, multicenter, randomized controlled trial including 500 patients with mild to moderate glaucoma undergoing cataract surgery, was completed as required for the PMA, according to the release. In that trial, patients were randomized to receive the micro-stent after cataract surgery or undergo no additional intervention.

The device met the COMPASS trial’s primary endpoint, showing that implantation of the device combined with cataract surgery yielded a 20% or greater reduction in IOP from baseline in significantly more eyes than cataract surgery alone at 1- and 2-year medication-free postoperative examinations, the release said.

“The CyPass micro-stent represents the next wave of innovation in the [minimally invasive glaucoma surgery] category,” Steven Vold, MD, a lead investigator for the study, said in the release. “It is encouraging to see the COMPASS results validated through such a large, robust pivotal study.”

Equinox Medical, LLC Negative Pressure Wound Therapy Pump and NPWT Wound Dressing Company. Launched their Halo MINI NPWT pump system in the US, Europe and Turkey.

npwt pump system, negative pressure wound therapy pump

Nurses from Venetian Care & Rehabilitation Center Honored at Statewide Conference for Their Service to Residents

Venetian Care & Rehabilitation Center nurse named as Assistant Director of Nursing of the Year, another received honorable mention as NJ LPN of the Year by New Jersey Association of Directors of Nursing Administration.

South Amboy, NJ (PRWEB) April 22, 2015

Two nurses at Venetian Care & Rehabilitation Center of South Amboy were honored this week for their exemplary kindness, knowledge and focus on residents by the New Jersey Association of Directors of Nursing Administration, the leading advocate and educational organization for directors and assistant directors of nursing and registered nurses in management positions.

Genine Bardinas, assistant director of nursing, was named New Jersey Assistant Director of Nursing of the Year, and LPN Joyce Brifu, received honorable mention as New Jersey LPN of the Year during the Association’s 26th annual conference at Bally’s Atlantic City on April 20.

“Our family of caregivers is proud to congratulate Genine and Joyce for this prestigious honor,” said Batsheva Katz, vice president at Windsor Healthcare Communities, the parent organization for Venetian and nine other short- and long-term care homes in New Jersey.

“Windsor Healthcare Communities is a pioneer in person-directed care that cherishes, honors and loves our residents,” Batsheva added. “I want to thank Genine and Joyce for putting residents first and making them feel like family.”

The annual NJADONA conference draws New Jersey nurses who serve in leadership positions throughout the state.

Genine, a wound care specialist and mother of four, joined Windsor Healthcare in 2013 because she appreciated the family-owned company’s commitment to providing person-directed care. She has served as assistant director of nursing at Briarwood Care & Rehabilitation and recently moved along with Briarwood staff and residents to Venetian, a brand new home located at 275 John T. O’Leary Blvd., near the South Amboy waterfront.

She values a holistic approach to nursing—considering all factors affecting a patient’s well-being—rather than focusing treatment just on a specific wound or illness. Nomination letters to NJADONA from a resident’s family member states that Genine is “caring, kind and goes above and beyond her calling.”

“I was born a nurse,” she said, with a chuckle. “Even as a child, I was always the nurse in charge, giving out all of the bandages.”

Joyce has worked with Windsor Healthcare four years, earning praise from administrators as well as residents and their families. In a nomination letter, Director of Nursing Yolanda Golebiowski said Joyce’s compassion and patience with residents has “earned their trust and created a home that evades loneliness and enhances their quality of life.”

About the New Jersey Association of Directors of Nursing Administration
The New Jersey Association of Directors of Nursing Administration is a network of nurse administrators and assistant directors of nursing in long-term care in New Jersey. The association endeavors to provide education, communication and service to the members it serves, supporting and promoting quality of care for those individuals receiving long-term care and concern for those delivering long-term care. Additional information can be found at

About Windsor Healthcare Communities
Windsor Healthcare Communities provides clinically sophisticated post-hospital medical care and rehabilitation, as well as comprehensive skilled nursing care throughout New Jersey. A family owned and operated organization, Windsor is a recognized pioneer in promoting person-directed care that cherishes, honors and loves our Elders. We are committed to medical excellence and well-being for all that we serve.

Equinox Medical, LLC is the fastest growing Negative Pressure Wound Therapy Pump Company in the wound care market int he United States.

Durable medical equipment rental company